- Second quarter total revenues of $264.6 million, up 9% year-over-year - Second quarter NUPLAZID® (pimavanserin) net product sales of $168.5 million, up 7% year-over-year - Second quarter DAYBUE ® (trofinetide) net product sales of $96.1 million, up 14% year-over-year - Raising low end of NUPLAZID net product sales guidance range to $665 to $690 million; reiterating all other prior 2025 guidance - Top-line results expected for COMPASS PWS Phase 3 study of ACP-101 in Prader Willi Syndrome in early Q4 2025 S ...

Core Viewpoint - Genmab A/S Sponsored ADR (GMAB) is currently positioned as a more attractive investment compared to Acadia Pharmaceuticals (ACAD) based on valuation metrics and earnings outlook [1][7]. Valuation Metrics - GMAB has a forward P/E ratio of 13.76, significantly lower than ACAD's forward P/E of 48.72, indicating GMAB is potentially undervalued [5]. - The PEG ratio for GMAB is 6.58, while ACAD's PEG ratio is slightly higher at 6.63, suggesting GMAB offers better value relative to its expected earnings growth [5]. - GMAB's P/B ratio stands at 2.62, compared to ACAD's P/B of 5.21, further supporting GMAB's valuation advantage [6]. Earnings Outlook - GMAB holds a Zacks Rank of 1 (Strong Buy), reflecting a positive earnings estimate revision trend, while ACAD has a Zacks Rank of 3 (Hold), indicating a less favorable earnings outlook [3][7]. - The solid earnings outlook for GMAB enhances its attractiveness as a value investment compared to ACAD [7].

Core Viewpoint - Acadia Pharmaceuticals is anticipated to report a year-over-year decline in earnings despite an increase in revenues for the quarter ended June 2025, with the actual results being crucial for its near-term stock price movement [1][2]. Financial Expectations - The consensus estimate for Acadia's quarterly earnings is $0.14 per share, reflecting a year-over-year decrease of 30%. Revenues are projected to be $260.28 million, representing a 7.6% increase from the previous year [3]. - The consensus EPS estimate has been revised down by 1.59% over the last 30 days, indicating a reassessment by analysts [4]. Earnings Surprise Potential - Acadia's Most Accurate Estimate is higher than the Zacks Consensus Estimate, resulting in an Earnings ESP of +17.43%, suggesting a bullish outlook from analysts [12]. - The stock holds a Zacks Rank of 3, indicating a likelihood of beating the consensus EPS estimate [12]. Historical Performance - In the last reported quarter, Acadia was expected to post earnings of $0.10 per share but exceeded this with earnings of $0.11, achieving a surprise of +10.00% [13]. - Over the past four quarters, Acadia has surpassed consensus EPS estimates three times [14]. Industry Context - In the Zacks Medical - Biomedical and Genetics industry, TG Therapeutics is expected to report earnings of $0.32 per share for the same quarter, indicating a year-over-year increase of 700%, with revenues projected at $136.04 million, up 85.2% from the previous year [18][19].

Company Overview - ACADIA Pharmaceuticals (ACAD) is a commercial-stage biopharmaceutical company focused on neurological and rare diseases [1] - The company's portfolio includes two commercial drugs, with NUPLAZID specifically targeting positive symptoms in Parkinson's disease [1] Industry Insights - The healthcare sector is complex, requiring financial professionals and investors to have scientific and clinical expertise to navigate effectively [1] - There is a growing need for bridging the gap between cutting-edge science and financial strategy to uncover hidden value and assess risks accurately [1]

Core Insights - Kamada (KMDA) and Acadia Pharmaceuticals (ACAD) are being compared for their value to investors, with KMDA currently showing a stronger potential for value investors [1] Valuation Metrics - KMDA has a forward P/E ratio of 23.88, significantly lower than ACAD's forward P/E of 42.40, indicating that KMDA may be undervalued [5] - The PEG ratio for KMDA is 0.96, while ACAD's PEG ratio is 4.51, suggesting that KMDA offers better value relative to its expected earnings growth [5] - KMDA's P/B ratio stands at 1.8, compared to ACAD's P/B of 4.58, further supporting the notion that KMDA is the more attractive investment option based on valuation metrics [6] Zacks Rank and Value Grades - KMDA holds a Zacks Rank of 2 (Buy), indicating a positive earnings outlook, while ACAD has a Zacks Rank of 3 (Hold) [3] - KMDA has a Value grade of A, whereas ACAD has a Value grade of C, reinforcing the conclusion that KMDA is the superior value option at this time [6]

Summary of Acadia Pharmaceuticals (ACAD) R&D Day - June 25, 2025 Company Overview - Acadia Pharmaceuticals focuses on advancing care for patients with underserved neurological and rare diseases, guided by a mission to address high unmet needs in these areas [4][5][11] - The company has two profitable brands, NUPLAZID and Debut, which are expected to generate over $1 billion in combined revenue for the first time in 2025 [5][11] Financial Performance - NUPLAZID is projected to achieve net sales between GBP $650 million and GBP $690 million in 2025, reflecting a 7% to 13% year-over-year growth [6] - Debut is expected to generate net sales between $380 million and $405 million, indicating a 916% growth [7] - The total peak sales potential for NUPLAZID and Debut combined could reach between $1.5 billion and $2 billion [12] Pipeline and Future Growth - Acadia has a robust pipeline with nine disclosed programs, eight of which are expected to be in clinical stages by the end of the year [17] - The company anticipates five study readouts from Phase II or Phase III trials between now and the end of 2027 [17] - The pipeline includes later-stage assets like ACP101 for Prader-Willi syndrome and ACP204 for Alzheimer's disease psychosis, with top-line data expected in 2025 and 2026, respectively [8][17] Key Pipeline Assets 1. **ACP204**: A novel 5-HT2A inverse agonist targeting Alzheimer's and Lewy body dementia psychosis, with a significant unmet need as there are currently no approved therapies for these conditions [24][60] - Approximately 3 million people are affected by psychosis related to these diseases [27] - ACP204 is designed to avoid QT prolongation, allowing for higher dosing and potentially greater efficacy [30][60] 2. **ACP211**: An oral agent with potential ketamine-like efficacy for major depressive disorder (MDD) and treatment-resistant depression (TRD), aiming to minimize sedation and dissociation [62][81] - MDD affects approximately 21 million adults in the U.S., with only 9 million receiving treatment [67] - The drug is designed to provide rapid antidepressant effects without the severe side effects associated with current treatments [81] Strategic Focus - Acadia's growth strategy is anchored in precision medicine, data innovation, globalization, and patient empowerment [4] - The company aims to expand into adjacent rare disease categories, leveraging its scientific approach and internal capabilities [11] Market Opportunity - The potential market for the pipeline assets is significant, with an estimated combined peak sales potential of up to $12 billion if all five pipeline assets succeed [12][13] - Acadia believes that the current market undervalues its clinical programs, and it is committed to delivering data and executing its strategy to unlock this potential [13] Conclusion - Acadia Pharmaceuticals is positioned for transformational growth through its innovative pipeline and strong commercial brands, addressing critical needs in neurological and rare diseases while aiming to enhance patient care and outcomes [2][4][11]

Financial Performance and Expectations - Acadia Pharmaceuticals expects to generate over $1 Billion in total U S revenues in 2025[12] - The company estimates a risk-adjusted peak sales potential of $25 Billion from its pipeline molecules[17] - The full potential peak sales for pipeline molecules is estimated at $12 Billion, assuming successful approval and commercialization[17] - Potential peak sales of current products are projected to be in the range of $15-$2 Billion[19] Pipeline Development and Strategy - Acadia Pharmaceuticals is focused on advancing care for underserved neurological and rare diseases[11] - The company has a late-stage pipeline with ACP-101 (P3-PWS) data expected in early Q4 2025 and ACP-204 (P2-ADP) data expected in mid-2026[12] - Acadia has 2 approved medicines and 9 disclosed and multiple undisclosed programs[30] - The company anticipates 7 Phase 2 or Phase 3 study starts in 2025 and 2026, and 5 Phase 2 or Phase 3 study readouts between 2025 and 2027[30] Key Programs and Indications - ACP-204 is being developed for Alzheimer's Disease Psychosis (ADP) and Lewy Body Dementia with Psychosis (LBDP), targeting approximately 3 million patients with psychosis across PDP, LBDP, and ADP in the US[45] - ACP-211 is in development for Major Depressive Disorder (MDD), a condition affecting approximately 21 million adults in the US[93, 125] - ACP-711 is being investigated for Essential Tremor (ET), which affects an estimated 7 million people or 22% of the US population[136, 171] - DAYBUE, approved for Rett syndrome, has seen >50% of patients remain on treatment at 12 months and 65% on treatment for 12+ months[271]

Core Insights - Investors in the Medical - Biomedical and Genetics sector may consider Kamada (KMDA) and Acadia Pharmaceuticals (ACAD) for potential value investments [1] - A strong Zacks Rank combined with a high Value category grade is identified as an effective strategy for finding value stocks [2] Valuation Metrics - Kamada has a Zacks Rank of 2 (Buy), indicating a positive earnings outlook, while Acadia Pharmaceuticals has a Zacks Rank of 3 (Hold) [3] - Kamada's forward P/E ratio is 21.64, significantly lower than Acadia's forward P/E of 45.77, suggesting Kamada may be undervalued [5] - Kamada's PEG ratio is 0.87, compared to Acadia's PEG ratio of 4.87, indicating better expected earnings growth relative to its price [5] - Kamada's P/B ratio is 1.63, while Acadia's P/B ratio is 4.99, further supporting Kamada's valuation advantage [6] - Based on these metrics, Kamada earns a Value grade of A, while Acadia receives a Value grade of C, positioning Kamada as the superior value option [6]

Summary of Acadia Pharmaceuticals (ACAD) FY Conference Call - June 09, 2025 Company Overview - **Company**: Acadia Pharmaceuticals (ACAD) - **Industry**: Biotechnology, specifically focusing on neurology and rare diseases Key Points and Arguments Management Changes and Strategic Priorities - Katherine Owen Adams has been with Acadia for eight months, implementing changes in the commercial structure, including the appointment of Tom Garner as CCO and Alison McMillan as head of the debut franchise [2][3] - Focus on accelerating clinical trial programs, with notable progress in the Prada Woolley trial, which is expected to complete earlier than anticipated [4] - Emphasis on both organic and inorganic growth strategies, including a deal signed with San Arena in December [5] Intellectual Property and Market Exclusivity - Acadia won a recent appeal on its composition of matter patent, extending exclusivity for NUPLAZID until October 2030, with total exclusivity lasting until February 2038 [8] - The company is prepared to compete with any potential generic formulations that may enter the market [10] Sales and Marketing Strategies - A new strategy to raise awareness of Parkinson's disease symptoms has been successful, leading to increased patient inquiries and the highest number of new prescriptions (NBRxs) since 2020 [14][15] - Direct-to-consumer campaigns have also contributed to patient growth, with a current market share of 20% for NUPLAZID [16] Patient Retention and Compliance - Over 50% of patients remain on NUPLAZID therapy after one year, with a reported 35% discontinuation rate in Q1, showing improvement in patient retention [30][32] - Management strategies have been enhanced to address gastrointestinal side effects, leading to better patient compliance [33] Pipeline Developments - ACP 204, a new five HT2A inverse agonist, is being developed to address limitations of NUPLAZID, with ongoing studies in Alzheimer's disease psychosis and Lewy body dementia psychosis [22][24][55] - Upcoming phase two data for ACP 204 is expected mid-next year, with a focus on efficacy and safety in a complex patient population [46][51] Regulatory and Geographic Expansion - Acadia has submitted for regulatory approval of debut in the EU, with potential approval expected in Q1 next year [34] - Plans for a phase III study in Japan are underway, indicating a strategic focus on international markets [35] Financial Position and Business Development Strategy - The company has a strong financial position with over $680 million in cash, allowing for continued investment in business development and pipeline funding [60][61] - Acadia aims to expand its focus from neurology to other rare diseases, leveraging management's experience in rare disease markets [59] Upcoming Events - An R&D Day is scheduled to showcase early data from pipeline molecules, indicating a commitment to transparency and stakeholder engagement [57] Additional Important Insights - The company is optimistic about the future growth of NUPLAZID, citing potential for increased market penetration and awareness among healthcare providers and caregivers [17][18] - The unmet need in the Alzheimer's and Lewy body dementia populations is significant, with no approved therapies currently available, highlighting the potential impact of Acadia's pipeline [53][54]

Company Overview - Acadia Pharmaceuticals has seen a share price increase of approximately 26.1% over the past month, outperforming the S&P 500 [1] - The most recent earnings report is crucial for understanding the catalysts affecting the stock [1] Earnings Estimates - Fresh estimates for Acadia have trended downward, with the consensus estimate shifting down by 20% [2] - The overall direction of estimate revisions indicates a downward shift in expectations for the stock [4] VGM Scores - Acadia has an average Growth Score of C, a Momentum Score of F, and a Value Score of C, placing it in the middle 20% for the value investment strategy [3] - The aggregate VGM Score for Acadia is D, which is significant for investors not focused on a single strategy [3] Market Outlook - Acadia holds a Zacks Rank of 3 (Hold), suggesting an expectation of in-line returns in the coming months [4] Industry Performance - Acadia is part of the Zacks Medical - Biomedical and Genetics industry, where Blueprint Medicines has gained 29.5% over the past month [5] - Blueprint Medicines reported revenues of $149.41 million for the last quarter, reflecting a year-over-year increase of 55.4% [5] - The expected loss for Blueprint Medicines in the current quarter is $0.54 per share, which represents a year-over-year improvement of 32.5% [6]